Biotech Values

[DewDiligence]

ABBV/ENTA—in addition to testing shorter 8-week regimens, it's notable that there are no extended-duration treatment arms (beyond 12 weeks) for cirrhotics. This could just be a decision based on the emerging competitive landscape, but is much more likely in response to some early data from the combo IMO.

I would say that both of the above—interim data and the competitive landscape—dictate that this second-generation regimen should be no longer than 12 weeks for any patient.